Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BEZAWIT TEKOLA

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1770742595
CMS profile
1304623
Location
FAIRFAX, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,986.18

89 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,986.18 89

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 89 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BEZAWIT TEKOLA

NPI 1770742595 · CMS profile ID 1304623

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

FAIRFAX, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 89 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770742595?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BEZAWIT TEKOLA, NPI 1770742595, CMS profile ID 1304623. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 89 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770742595?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BEZAWIT TEKOLA, NPI 1770742595, CMS profile ID 1304623. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 89 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770742595?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BEZAWIT TEKOLA, NPI 1770742595, CMS profile ID 1304623, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 89 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1770742595?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

89 matching records · $1,986.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 89 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 89.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $26.0512/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231818775 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.2712/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231818781 CMS
Gilead Sciences, Inc. $24.6512/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234478046 CMS
Celltrion USA Inc. $26.6412/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250833233 CMS
QOL Medical, LLC $23.2012/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185026586 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.2412/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223867890 CMS
PFIZER INC. $10.7712/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231181838 CMS
Phathom Pharmaceuticals, Inc. $15.2412/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219274100 CMS
Gilead Sciences, Inc. $14.9711/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234572214 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.2211/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223850753 CMS
ABBVIE INC. $12.9611/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204497354 CMS
Pharmacosmos Therapeutics Inc. $16.4411/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250731314 CMS
Janssen Biotech, Inc. $123.4811/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175230117 CMS
Madrigal Pharmaceuticals $24.1710/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248315816 CMS
PFIZER INC. $24.9010/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230734474 CMS
ABBVIE INC. $27.7110/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204497348 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.2110/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223842402 CMS
Celltrion USA Inc. $34.1410/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250833231 CMS
ABBVIE INC. $27.8010/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204497344 CMS
ORPHALAN INC $24.8310/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243933321 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.7410/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223823946 CMS
Janssen Biotech, Inc. $0.2710/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175231544 CMS
Janssen Biotech, Inc. $27.6210/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175233016 CMS
Phathom Pharmaceuticals, Inc. $14.8710/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219274098 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.2210/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223850751 CMS
ABBVIE INC. $24.2810/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204497340 CMS
Gilead Sciences, Inc. $16.7409/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234559931 CMS
Gilead Sciences, Inc. $21.6409/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234509129 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.5809/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223886166 CMS
PFIZER INC. $21.8509/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229680216 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.3909/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223835690 CMS
Janssen Biotech, Inc. $21.0209/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175229011 CMS
Novo Nordisk Inc $24.9309/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188286523 CMS
Madrigal Pharmaceuticals $22.6308/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248315814 CMS
Janssen Biotech, Inc. $18.2908/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175227468 CMS
Lilly USA, LLC $18.3108/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186527983 CMS
Gilead Sciences, Inc. $16.6508/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234560689 CMS
ABBVIE INC. $22.2308/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204497335 CMS
Janssen Biotech, Inc. $22.0907/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175232363 CMS
ABBVIE INC. $1.1007/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204497328 CMS
ABBVIE INC. $21.4907/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204497330 CMS
ABBVIE INC. $2.0107/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204497320 CMS
ABBVIE INC. $16.9807/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204497324 CMS
Janssen Biotech, Inc. $18.8707/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175228233 CMS
Gilead Sciences, Inc. $22.7207/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234497632 CMS
Medtronic, Inc. $17.8807/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219042862 CMS
ABBVIE INC. $14.7507/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204497316 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.8206/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223855737 CMS
Lilly USA, LLC $20.6706/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186533655 CMS
Aimmune Therapeutics, Inc. $23.3806/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249670154 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,039.04 76
PY2020 $454.06 31
PY2021 $513.43 28
PY2022 $1,500.48 85
PY2023 $1,316.10 76
PY2024 $1,422.82 66
PY2025 $1,986.18 89

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $63.82 1
PY2024 Principal investigator $814.08 1
PY2023 Principal investigator $33,698.06 8
PY2022 Principal investigator $83,729.01 12
PY2021 Principal investigator $46,132.10 21
PY2020 Principal investigator $113,515.53 46
PY2019 Principal investigator $119,167.67 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $1,737.42 12/31/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670122229
Principal investigator 1 Allergan Inc. $700.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670115267
Principal investigator 1 Allergan Inc. $10,332.20 12/17/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 670116327
Principal investigator 1 Gilead Sciences, Inc. $52.00 11/20/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676528054
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670099871
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100039
Principal investigator 1 Allergan Inc. $955.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100113
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100397
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100859
Principal investigator 1 Janssen Research & Development, LLC $1,870.25 09/30/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 654264791
Principal investigator 1 Allergan Inc. $4,132.50 09/19/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670077767
Principal investigator 1 Gilead Sciences, Inc. $1,100.00 08/28/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528051
Principal investigator 1 Allergan Inc. $1,757.50 08/22/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670067945
Principal investigator 1 Allergan Inc. $1,100.00 08/22/2019 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW BOARD
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670068269
Principal investigator 1 Gilead Sciences, Inc. $52.00 08/21/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676528045
Principal investigator 1 Allergan Inc. $3,297.00 08/15/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670065943
Principal investigator 1 Gilead Sciences, Inc. $600.00 08/12/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528035
Principal investigator 1 Gilead Sciences, Inc. $2,195.00 08/12/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528041
Principal investigator 1 Allergan Inc. $4,965.65 07/09/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670055619
Principal investigator 1 Gilead Sciences, Inc. $2,288.00 06/19/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528029
Principal investigator 1 Allergan Inc. $750.00 06/11/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670051393
Principal investigator 1 Gilead Sciences, Inc. $9,022.00 05/29/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676528025
Principal investigator 1 Allergan Inc. $665.00 05/22/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670047453
Principal investigator 1 Allergan Inc. $10,000.00 05/09/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670044507
Principal investigator 1 Allergan Inc. $10,000.00 05/09/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670044511
Principal investigator 1 Allergan Inc. $750.00 05/09/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670044515
Principal investigator 1 Allergan Inc. $928.15 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670039797
Principal investigator 1 Allergan Inc. $3,000.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040127
Principal investigator 1 Allergan Inc. $115.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040201
Principal investigator 1 Allergan Inc. $115.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040203
Principal investigator 1 Allergan Inc. $115.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040206
Principal investigator 1 Allergan Inc. $115.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040265
Principal investigator 1 Allergan Inc. $115.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040343
Principal investigator 1 Allergan Inc. $115.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040405
Principal investigator 1 Allergan Inc. $180.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040409
Principal investigator 1 Allergan Inc. $115.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040413
Principal investigator 1 Allergan Inc. $3,000.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040415
Principal investigator 1 Allergan Inc. $115.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040419
Principal investigator 1 Allergan Inc. $180.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040481
Principal investigator 1 Allergan Inc. $115.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040485
Principal investigator 1 Allergan Inc. $50.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040489
Principal investigator 1 Allergan Inc. $50.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040495
Principal investigator 1 Allergan Inc. $50.00 04/23/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040504
Principal investigator 1 Allergan Inc. $10,000.00 03/21/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670032707
Principal investigator 1 Allergan Inc. $750.00 03/21/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670032871
Principal investigator 1 Gilead Sciences, Inc. $7,089.00 03/20/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528019
Principal investigator 1 Gilead Sciences, Inc. $6,513.00 02/20/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528013
Principal investigator 1 Allergan Inc. $5,000.00 01/31/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670020985
Principal investigator 1 Allergan Inc. $500.00 01/31/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670020999
Principal investigator 1 Gilead Sciences, Inc. $2,200.00 01/28/2019 Non-covered Recipient Entity
VERITY RESEARCH INC
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676528009
Principal investigator 1 Allergan Inc. $3,773.40 01/22/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670018481
Principal investigator 1 Allergan Inc. $6,087.60 01/08/2019 Non-covered Recipient Entity
VERITY RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670015081